BACKGROUND: Breast cancer bone metastasis is a complication that significantly compromises patient survival due, in part, to the lack of disease-specific biomarkers that allow early and accurate diagnosis. METHODS: Using mass spectrometry protein profiling, plasma samples were screened from three independent breast cancer patient cohorts with and without clinical evidence of bone metastasis. RESULTS: The results identified 13 biomarkers that classified all 110 patients with a sensitivity of 91% and specificity of 93% [receiver operating characteristics area under the curve (AUC = 1.00)]. The most discriminatory protein was subsequently identified as a unique 12-48aa peptide fragment of parathyroid hormone-related protein (PTHrP). PTHrP(12-48) was significantly increased in plasma of patients with bone metastasis compared with patients without bone metastasis (P < 0.0001). Logistic regression models were used to evaluate the diagnostic potential of PTHrP(12-48) as a single biomarker or in combination with the measurement of the clinical marker N-telopeptide of type I collagen (NTx). The PTHrP(12-48) and NTx logistic regression models were not significantly different and classified the patient groups with high accuracy (AUC = 0.85 and 0.95), respectively. Interestingly, in combination with serum NTx, the plasma concentration of PTHrP(12-48) increased diagnostic specificity and accuracy (AUC = 0.99). CONCLUSIONS: These data show that PTHrP(12-48) circulates in plasma of patient with breast cancer and is a novel and predictive biomarker of breast cancer bone metastasis. Importantly, the clinical measurement of PTHrP(12-48) in combination with NTx improves the detection of breast cancer bone metastasis. IMPACT: In summary, we present the first validated, plasma biomarker signature for diagnosis of breast cancer bone metastasis that may improve the early diagnosis of high-risk individuals.
BACKGROUND:Breast cancer bone metastasis is a complication that significantly compromises patient survival due, in part, to the lack of disease-specific biomarkers that allow early and accurate diagnosis. METHODS: Using mass spectrometry protein profiling, plasma samples were screened from three independent breast cancerpatient cohorts with and without clinical evidence of bone metastasis. RESULTS: The results identified 13 biomarkers that classified all 110 patients with a sensitivity of 91% and specificity of 93% [receiver operating characteristics area under the curve (AUC = 1.00)]. The most discriminatory protein was subsequently identified as a unique 12-48aa peptide fragment of parathyroid hormone-related protein (PTHrP). PTHrP(12-48) was significantly increased in plasma of patients with bone metastasis compared with patients without bone metastasis (P < 0.0001). Logistic regression models were used to evaluate the diagnostic potential of PTHrP(12-48) as a single biomarker or in combination with the measurement of the clinical marker N-telopeptide of type I collagen (NTx). The PTHrP(12-48) and NTx logistic regression models were not significantly different and classified the patient groups with high accuracy (AUC = 0.85 and 0.95), respectively. Interestingly, in combination with serum NTx, the plasma concentration of PTHrP(12-48) increased diagnostic specificity and accuracy (AUC = 0.99). CONCLUSIONS: These data show that PTHrP(12-48) circulates in plasma of patient with breast cancer and is a novel and predictive biomarker of breast cancer bone metastasis. Importantly, the clinical measurement of PTHrP(12-48) in combination with NTx improves the detection of breast cancer bone metastasis. IMPACT: In summary, we present the first validated, plasma biomarker signature for diagnosis of breast cancer bone metastasis that may improve the early diagnosis of high-risk individuals.
Authors: Josep Villanueva; Andrew J Martorella; Kevin Lawlor; John Philip; Martin Fleisher; Richard J Robbins; Paul Tempst Journal: Mol Cell Proteomics Date: 2006-08-08 Impact factor: 5.911
Authors: Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta Journal: Lancet Date: 2002-02-16 Impact factor: 79.321
Authors: Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes Journal: Lancet Oncol Date: 2007-02 Impact factor: 41.316
Authors: Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major Journal: Cancer Treat Rev Date: 2008-06-24 Impact factor: 12.111
Authors: Allan Lipton; Guenther G Steger; Jazmin Figueroa; Cristina Alvarado; Philippe Solal-Celigny; Jean-Jacques Body; Richard de Boer; Rossana Berardi; Pere Gascon; Katia S Tonkin; Robert Coleman; Alexander H G Paterson; Mark C Peterson; Michelle Fan; Amy Kinsey; Susie Jun Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Sudeepa Bhattacharyya; Eric R Siegel; Sara J Achenbach; Sundeep Khosla; Larry J Suva Journal: J Bone Miner Res Date: 2008-07 Impact factor: 6.741
Authors: Archana Kamalakar; Manali S Bendre; Charity L Washam; Tristan W Fowler; Adam Carver; Joshua D Dilley; John W Bracey; Nisreen S Akel; Aaron G Margulies; Robert A Skinner; Frances L Swain; William R Hogue; Corey O Montgomery; Parshawn Lahiji; Jacqueline J Maher; Kim E Leitzel; Suhail M Ali; Alan Lipton; Richard W Nicholas; Dana Gaddy; Larry J Suva Journal: Bone Date: 2014-01-28 Impact factor: 4.398
Authors: Archana Kamalakar; Charity L Washam; Nisreen S Akel; Bethany J Allen; Diarra K Williams; Frances L Swain; Kim Leitzel; Allan Lipton; Dana Gaddy; Larry J Suva Journal: J Bone Miner Res Date: 2017-04-19 Impact factor: 6.741